America has long led the world in medical innovation – which brings breakthrough, lifesaving medicines to people around the world, and supplies 4.5 million biopharmaceutical jobs to American workers. But to ensure the industry continues to deliver these benefits, the U.S. needs a level playing field when it comes to international trade.
Unfortunately, U.S. trade partners – including Argentina, China, India, Indonesia, Russia, Turkey and Vietnam – are resorting to “localization barriers” which unfairly discriminate against U.S. products. These barriers put U.S. biopharmaceutical products at a disadvantage and flout obligations set out in international trade agreements. The result is contorted market incentives, undermined innovation and restricted patient access to lifesaving treatments.
Take Turkey and Russia, for example. Both employ discriminatory localization barriers, including:
- Discriminatory local inspection requirements. Turkey requires all biopharmaceutical products to go through a burdensome and opaque certification process for market entry, as well as full on-site inspections for importation despite lacking sufficient resources to complete these inspections, resulting in significant market entry delays, or outright restrictions, for lifesaving products produced by U.S. manufacturers.
- Coercive local manufacturing and tech transfer rules. In Russia, only biopharmaceutical products tested in local clinical trials may be submitted for registration. Meanwhile, in Turkey, domestic biopharmaceutical products enjoy higher reimbursement and quicker regulatory approval. A foreign product can only access these if the manufacturer agrees to transfer its intellectual property data to Turkish authorities, creating unfair windfalls for domestic firms that can copy and market the innovative product.
- Closed government procurement processes. Both Turkey and Russia give price advantages to local biopharmaceutical products purchased by the government – allowing local products to secure government contracts even if they are more expensive than imports. Additionally, Russia outright bans foreign products from government contracts if two or more regional companies have provided bids.
The costs and consequences of illegal trade barriers such as these are severe – they disadvantage U.S. companies in the global marketplace, compromise access to lifesaving medicine, and ultimately hurt patients in both countries. It’s time to level the playing field for the U.S. and the rest of the world.
Jay Taylor
Jay Taylor is Executive Vice President of International Advocacy at PhRMA. Prior to Joining PhRMA, Jay was a partner at the international law firm, McDermott, Will & Emery, where he specialized in international trade policy, export controls and Foreign Corrupt Practices Act (FCPA) matters. Previously, Jay served as Associate General Counsel at the Office of the United States Trade Representative (USTR), where he managed and litigated numerous international trade disputes, and drafted and negotiated several free trade agreements. Mr. Taylor received his undergraduate degree from Princeton University, and a law degree from Tulane University.
Jay Taylor
Bayh-Dole: The fuel for America’s innovation engine
Setting the record straight: 3 facts about drug patents
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
MFN could disrupt the affordable medicines patients depend on
Intellectual Property and Hatch-Waxman: A blueprint for American leadership and patient savings
Argentina sets course to enable innovation by rejecting failed patent rules
16 years later: How BPCIA continues to expand competition and lower costs
Key context is often missing from the debate over the Patent Trial and Appeal Board
MFN undermines U.S. biopharmaceutical innovation
Updated Analysis Underscores the Need for Brazil to Address Patent Backlogs
How post-approval innovation keeps delivering for patients
PhRMA calls on USTR to ensure foreign nations pay their fair share
Three things to know about Bayh-Dole: Innovation that pays off for taxpayers
Delivering breakthroughs and lower costs for patients
PBMs, not patents, are blocking access to lower-cost medicines
New report: How intellectual property drives U.S. innovation and biopharma's impact
New report: Post-approval innovation delivers substantial patient benefits
Tariffs on medicines would harm American competitiveness, industry and patients
The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers
USTR 2025 Special 301 Report corrects course
From sound to science: How IP powers innovation in music and hearing
How the IRA is impacting the generic drug market
3 myths critics get wrong about intellectual property
ICYMI: PhRMA submits comments to White House on artificial intelligence
Strong Trade Policies Protect American Workers and Biopharmaceutical Innovation
USTR remembers—three years later—that it announced a trade initiative with Europe
PhRMA submission calls for USTR to correct course on trade policy, enforcement
40 Years of Hatch-Waxman: How Can We Secure its Legacy?
40 Years of Hatch-Waxman: How does the Hatch-Waxman Act help patients?
40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?
New research: American biopharmaceutical investment in R&D drives transformational innovation
Biden Administration report debunks myths around patent “evergreening” and “thickets”
What to know about the latest effort to break patents using a legally dubious avenue
WTAS: Proposed Unsubstantiated USPTO Rule Change is a Threat to American Innovation
No Region Left Behind: USTR expands its unambitious trade agenda to the western hemisphere
PhRMA launches education campaign on the benefits of America's IP system
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
Experts discuss the value of IP at Senate Judiciary Committee hearing
World Trade Week 2024: Time for a more ambitious U.S. trade agenda
World IP Day 2024: Supporting an innovative and sustainable future
Why won’t USTR strengthen medical supply chains with America’s allies?
The impact of innovative medicines: A caregiver's perspective
International meetings hold big implications for Americans and our innovation ecosystem
Proposed march-in framework would chill American innovation
PhRMA 2024 Special 301 submission: USTR needs to support American innovation, global access to medicines
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
What they are saying: Experts agree that proposed march-in framework would jeopardize innovation
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
The White House continues to attack American innovation
Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation
Misuse of march-in could stifle innovation
WHO Pandemic Agreement offers opportunities and risks for American innovators
Word of the Month: The Bayh-Dole Act
PhRMA submission: USTR needs more ambition to combat unfair trade barriers
It’s PBMs, not patents, blocking competition
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
New PhRMA site demonstrates how a technology-driven health care system brings benefits to patients
The Biden Administration has failed to advance an inclusive, worker-centered trade agenda
WTAS on reasonable pricing and public-private partnerships
Key considerations as Congress works towards PAHPA reauthorization
Reject efforts to undermine America’s R&D ecosystem
Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth
Setting the record straight on the Bayh-Dole Act and March-in
World IP Day 2023: Celebrating women leaders in innovation
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
New global analysis shows patient access challenges around the world
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
U.S. biopharmaceutical exports support jobs, innovation
Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?
PhRMA submits comments to USPTO highlighting important role of patent system in medicine development
U.S. must address IP and market access barriers abroad to protect American innovation
Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade
Expanding TRIPS waiver would jeopardize biopharmaceutical research and development
Six ways I-MAK is lying about biopharma patents
TRIPS waiver expansion risks public health
Expanding the WTO intellectual property waiver will hurt American jobs
PhRMA submission to USTR calls for urgent defense of American innovation abroad
The law driving technology transfer and fostering innovation
Don’t take anti-innovation, activist funded academics at their word
New report ignores benefits of patent system to innovation and patients
Partnerships are driving global COVID-19 treatment access
The dangers of expanding the TRIPS waiver
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
Patent policy changes proposed by USPTO and FDA would leave patients behind
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
Biden Administration details inadequate protection of American intellectual property and foreign barriers to innovation abroad
PhRMA encourages Biden administration to pursue ambitious Indo-Pacific Economic Framework
Research and development continues long after a medicine is initially approved
Protecting U.S. innovation abroad to support economic and pandemic recovery
Legislation threatens patent protections and future innovation
Global COVID-19 vaccination matters now and for the future
New report highlights importance of IP-intensive manufacturing industries to the U.S. economy
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
Strengthening the WTOs global trade and health agenda
Patients and innovators lose if the government pursues ‘march-in’
Supporting country readiness to boost global vaccine access
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
Increasing global access to vaccines by optimizing production
Dose sharing as a part of the COVID-19 global vaccine equity strategy
Promoting global vaccine equity while protecting innovation
IP Explained: How does the U.S. patent process work?
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
The Biden Administration allows politics to upend a pragmatic pandemic response
New report demonstrates development of new medicines relies on private sector expertise and investment
American leadership on innovation policy is essential to global health progress
Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections
Intellectual property is the key to vaccine development, manufacturing and technology sharing
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
Preserving U.S. innovation worldwide is more important than ever
New video: See how strong IP protections lead to stronger treatments for patients
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
The latest: What they are saying: Importance of intellectual property protections to combat COVID-19
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
IP Explained: Intellectual property system working to combat COVID-19
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
The continued imperative to protect U.S. innovation worldwide
IP Explained: Four key takeaways from new Bayh-Dole white paper
Trump administration must defend and protect U.S. innovation
PhRMA submission to 2020 National Trade Estimate Report: Urgent action required to protect U.S. biopharmaceutical innovation
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act
IP Explained: Four things to know about the Bayh-Dole Act
IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle
IP Explained: Understanding biopharmaceutical innovation
IP Explained: Why IP protections are important for biologic medicines
Setting the record straight on international reference pricing
IP Explained: What is Section 101 and why reforms are needed
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
World Trade Month: How we can expand world-class pro-innovation standards
IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry
IP Explained: What they are saying on the importance of strong intellectual property protections
IP Explained: Why patents are so critical to biopharmaceutical innovation
New report: Using march-in authority would jeopardize U.S. innovation
Special 301 submission calls for a level playing field for American innovators
Fact Check: Biologics, regulatory data protection and the United States-Mexico-Canada Agreement
PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
Five myths about global efforts to combat tuberculosis
Here’s how America’s biopharmaceutical companies lead the way in development of innovative new medicines
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
Celebrating U.S. innovation as USPTO issues the 10 millionth patent
Supreme Court decisions in two cases pave way for IPR reforms
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements
What is inter partes review and why does it matter?
Supporting opportunities for enhanced competition in the marketplace
Biopharma leads sustained economic growth driven by IP-intensive industries
Opportunities to build upon enhanced competition for medicines in the marketplace
Poll respondents appreciate economic benefits of innovation and call for more protections
As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority
Foreign government price setting by any name harms innovation and access to medicines
Compulsory licensing: A misused and abused international trade law
Government-imposed price controls threaten innovation and access
ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation
Trading fair means upholding the law: A focus on patents
New nonprofit – I-ACT for Children – launches to promote innovative medicines development for young patients in need
Enforcing unmet trade obligations protects U.S. innovation
NAFTA tribunal fails to rule on Canada’s patent utility doctrine
PhRMA urges USTR to protect American innovators abroad
Illegal trade barriers discriminate against U.S. innovators
Intellectual Property
Patents
Trade
Illegal trade barriers discriminate against U.S. innovators
Illegal trade barriers discriminate against U.S. innovators